Board of Directors

 

Kazuo Nakamura, Ph.D.
Founder
Representative Director, Chairman and Chief Executive Officer, CMIC HOLDINGS Co., Ltd.

Dr. Nakamura is our Chairman and CEO. He started a first CRO in Japan in 1992 and greatly contributed to found the Japan CRO Association with three other companies working in the field at that time Dr. Nakamura served as secretariat for 5 years from its establishment. As a chairman of the Japan CRO Association from 1999 until 2002, Dr. Nakamura dedicated his time and broad network in this industry to expand the Association and the CRO industry in Japan as a whole. The history of CMIC directly reflects the history of CROs in Japan. Prior to founding CMIC, Dr. Nakamura was a project team leader of the development of Pravastatin, a blockbuster drug primarily used for the treatment of dyslipidemia and the prevention of cardiovascular disease, in Sankyo Co., Ltd.

Dr. Nakamuara earned his bachelor’s degree from Faculty of Pharmaceutical Sciences, Kyoto University and doctoral degree from Graduate School of Natural Science & Technology, Kanazawa University.

Dr. Nakamura said, “CMIC Group pioneered the CRO business in Japan. We started out to support the development of pharmaceuticals, and it now offers greatly expanded services that encompass an entire value-chain of pharmaceutical companies, including manufacturing, sales, and marketing, based on our unique “Pharmaceutical Value Creator (PVC)” business model. We also offer services to medical device manufacturers, academia, bio-ventures, and medical institutions. We also provide prophylaxis and health enhancing services to the public. We will continue to establish business models that create further value and contribute to greater advances in the pharmaceutical industry.”

Keiko Oishi
Representative Director, President and Chief Operating Officer, Supervisory Manager of Business Development & Marketing, CMIC HOLDINGS Co., Ltd.

Ms. Oishi is the President and COO, Supervisory Manager of Business Development & Marketing of CMIC HOLDINGS Co., Ltd., responsible for group-wide business execution.

Ms. Oishi received her Master of Science degree from the University of Tokyo. She started her career at Nikkei McGraw-Hill, Inc. in Japan (now renamed Nikkei Business Publications), as a staff writer for Nikkei Biotech, the first Japanese newsletter specializing in biotechnology. She accumulated her biotechnology industry career through working in Genzyme Japan, Ltd., and Genentech, Ltd., a Japanese Branch of Genentech, Inc. in the U.S.

Ms. Oishi joined CMIC in 1996, as Manager of the Strategy Development Department. Over the past 20 years, she has been responsible for International Business and Corporate Development, covering Japan, Korea, China, Singapore, Taiwan and other regions in Asia Pacific, as well as for International Business Development which function could bring in foreign pharma and biotech companies that are interested in drug development in Japan and Asia, to start their regulatory and clinical activities in the region. With her broad international experience and strong leadership, she continuously leads the company to further globalization.

Wataru Mochizuki
Corporate Director, Executive Vice President and Chief Financial Officer, Supervisory Manager of Administration and Support Unit, the Company, CMIC HOLDINGS Co., Ltd.

Mr. Mochizuki joined CMIC in 2005 as an executive officer for internal control and corporate finance and was assigned as Chief Financial Officer in 2012. Since then, he has been responsible for directing the fiscal functions of the corporation in accordance with generally accepted accounting principles and other regulatory and advisory organizations and in accordance with financial management techniques and practices appropriate within the industry. Prior to CMIC, Mr. Mochizuki served as a corporate officer for finance at the US-based venture company of the networking device and led the company to achieve the IPO on the Second Section of the Tokyo Stock Exchange. Served as various senior roles in finance, Mr. Mochizuki contributed to develop corporate strategy and establish cross-functional partnerships in the financial point of view. Mr. Mochizuki started his career outside the healthcare industry until he joined Site Support Institute Co., Ltd., Site Management Organization of CMIC Group; however, as pharmaceutical companies and other healthcare industries faced revolutionary changes, he would play a part of the leadership roles in CMIC Group bringing innovation in this industry by providing new services and products.
Mr. Mochizuki received a bachelor of arts in Commerce from WASEDA University.

Makoto Matsukawa
Corporate Director and Executive Vice President, Supervisory Manager of CDMO, CMIC HOLDINGS Co., Ltd.

Mr. Matsukawa joined CMIC in 2012 as an executive officer for Corporate Planning and IPD business. Since 2013, he has been responsible for Corporate Business Development. Mr. Matsukawa started the first 15 years of his career at pharmaceutical and medical device companies, such as Baxter Healthcare. He made his career move to join Starbucks Coffee Japan as head of HR to build business foundation and also served as the head of marketing. Mr. Matsukawa became head of HR and corporate planning at Pacific Golf Management owned by Lone Star, where he turned around bankrupt golf course companies to achieve IPO listing at Tokyo Stock Exchange. Prior to joining CMIC, Mr. Matsukawa served as the head of HR/VP at Quintiles Japan. Currently, Mr. Matsukawa is the Representative Director & CEO of CMIC CMO Co. Ltd. (CDMO business) , as well as board member and Executive Vice President of CMIC HOLDINGS Co., Ltd.

Toru Fujieda
Corporate Director and Executive Vice President, Supervisory Manager of Clinical CRO,Corporate Director, CMIC HOLDINGS Co., Ltd.

Mr. Fujieda is the President of CMIC Co., Ltd. and he is a board member and Executive Vice President of CMIC HOLDINGS. He joined the company in 2016. Prior to joining CMIC, Mr. Fujieda served as Vice President, Clinical Execution, at Daiichi Sankyo Co., Ltd., and was responsible for vendor selection and management of contract research organizations. Mr. Fujieda first joined Sankyo in 1984, and focused on drug development. He contributed significantly to the development of two new drugs including Pravastatin, the first blockbuster statin drug in the world used for the treatment of dyslipidemia. He also contributed significantly to the development of Laninamivir, a single shot neuraminidase inhibitor for the treatment and prophylaxis of Influenzavirus A and Influenzavirus B. After 30 years of service at Sankyo and Daiichi Sankyo, Mr. Fujieda decided to join CMIC, the No.1 CRO in Japan, because of CMIC’s successful history of providing a variety of CRO services for new drug development. Since joining CMIC, Mr. Fujieda has contributed to the development of new drugs, medical devices, regenerative medicine products, quasi-drugs, cosmetics, and various additional healthcare innovations. Mr. Fujieda received a master’s degree in Pharmacy from Kyushu University.

Philippe Auvaro
Corporate Director and Executive Vice President, Supervisory Manager of Orphan Drug Business, CMIC HOLDINGS Co., Ltd.

Mr. Auvaro has been the President of OrphanPacific, Inc. since 2016. OrphanPacific, Inc. is a joint venture between CMIC Group and MEDIPAL Group. Mr. Auvaro has been a member of the board of CMIC HOLDINGS Co., Ltd. since 2016. He is responsible for supporting CMIC Group in Japan and worldwide to develop the pharmaceutical value creator concept for pharmaceutical industry clients. Additionally, he is responsible for helping patients in Japan gain access to rare disease treatments. Prior to joining CMIC Group, he established and was President of the Japan-based affiliate of Aspen Pharmacare, which is one of the largest generics manufactures in the world. Mr. Auvaro spent the 25 year period prior to joining Aspen holding various senior management positions at companies including GlaxoSmithKline in Japan, the Aventis joint-venture in Korea, Handok Pharmaceuticals in Korea, Aventis in Taiwan, and Roussel in various countries in the Asia-Pacific region. He received a bachelor’s degree in Management & Finance from ESLSCA Business School in France. He also completed the master’s of art exchange program with Sophia University (Japan) in Corporate Finance.

Yoshiyuki Hano
Corporate Director, Executive Vice President and Chief Human Officer, Supervisory Manager of Administration and Support Unit, CMIC HOLDINGS Co., Ltd.

Mr. Hano has been CMIC’s Chief Human Resources Officer since 2012. He is responsible for the global management of CMIC’s human resources function, including talent acquisition, learning and development, and organizational development. Prior to joining CMIC, Mr. Hano served as Director of Human Resources at Quintiles International Japan between 2011 and 2012. At Quintiles, he led the design and launch of the company’s talent management system. Before joining Quintiles, Mr. Hano was with AstraZeneca K.K. for more than 25 years, focusing primarily on sales and business development. He led several major sales division initiatives, which resulted in improved sales performance. Mr. Hano also led the organizational transition project team for the acquisition of Astra and Zeneca in 2000. During his 30 year career in the healthcare industry, Mr. Hano has seen firsthand the positive societal impact of many types of healthcare products. Looking forward, he wants to contribute to the development of innovative products that improve patient lives. Mr. Hano received a bachelor’s degree in Economics from Ritsumeikan University.

Akihisa Mitake
Corporate Director and Executive Vice President, Supervisory Manager of Healthcare, CMIC HOLDINGS Co., Ltd.

Mr. Mitake has been the President of Site Support Institute Co., Ltd. since 2016. Site Support is a leading site management organization (SMO) in Japan. It is a subsidiary of CMIC. Mr. Mitake joined CMIC Clinical Operations in 1993. He was an early member of the team that established CMIC’s CRO business in Japan until 2004. From 2004 to 2007, Mr. Mitake served as the President of GreenPeptide Co., Ltd. (now BrightPath Biotherapeutics Co., Ltd.), which is a venture company that was started out of Kurume University. GreenPeptide performs research and development, manufacturing, and marketing for onco-immunotherapy drugs. He spearheaded the first-in-human clinical trials for cancer peptide vaccines on patients with hormone-refractory prostate cancer and glioblastoma in Japan. He raised 3 billion Japanese yen of venture capital to fund these phase 2 trials. After returning to CMIC in 2007, Mr. Mitake held several senior management roles including branch office manager, executive director of CMIC Korea, corporate officer for business development, President of CMIC PMS and the CMIC BIORESEARCH CENTER. His innovative work has helped CMIC obtain a patent on CRO industry report documentation systems. Prior to joining CMIC in 1993, Mr. Mitake was a project leader for several drugs in clinical operations in TAIHO Pharmaceutical Co., Ltd. His mother was diagnosed with an unknown eye disorder when he was in elementary school. This was instrumental in Mr. Mitake’s decision to pursue a career in the healthcare field. He has strived to develop innovative drugs, preventive medicine, and personalized medicine. Mr. Mitake received a bachelor’s degree in Pharmacy from Toho University. Pharmacist.

External Corporate Director

Akira Nakamuara
External Corporate Director

April 1968 Joined The Sanwa Bank, Ltd. (currently, The Bank of Tokyo-Mitsubishi UFJ, Ltd.)
June 1994 Director of The Sanwa Bank, Ltd.
May 1997 Managing Director of The Sanwa Bank, Ltd.
June 1999 President of Sanwa Capital Finance Ltd. (Mitsubishi UFJ Capital Co., Ltd.)
June 2005 The Chairman and Director of Ask Planning Center, Inc.
July 2005 The Chairman of CREEK & RIVER Co., Ltd.
March 2011 The President of Medical Principle Co., Ltd. (to present)
December 2014 External Corporate Director of CMIC HOLDINGS Co., Ltd. (to present)
June 2017 Chairman and Director, ASK HOLDINGS, INC. (to present)
June 2017 Chairman and Director, Wealth Management, Inc. (to present)

Status of Important Concurrent Posts
-The President of Medical Principle Co., Ltd.
-The Chairman and Director of ASK HOLDINGS, INC.
-The Chairman and Director of Wealth Management, Inc.

Shinji Kobayashi
External Corporate Director

April 1972 Joined ITOCHU Corporation.
June 1989 External assignment for Nihon Parking Card K.K. (currently NIHON PARKING CORPORATION), Representative Director of Nihon Parking Card K.K.
July 1992 Resigned from President of Nihon Parking Card K.K.
April 1994 President of Nihon Parking Card K.K.
March 2000 Resigned from ITOCHU Corporation, Representative Director of NIHON PARKING CORPORATION
May 2011 The Chairman of the Board of Directors of NIHON PARKING CORPORATION
December 2012 Resigned from NIHON PARKING CORPORATION
October 2013 President and Representative Director in IPI Co., LTD. (to present)
December 2015 External Corporate Director of CMIC HOLDINGS Co., Ltd. (to present)

Status of Important Concurrent Posts
-President and Representative Director in IPI Co., LTD.

Masaru Iwasaki, M.D. & Ph.D.
External Corporate Director

December 1973 The University of Tokyo
April 1983 Department of Surgery II, Faculty of Medicine, University of Yamanashi
April 1993 Joined Hoechst Japan Co., Ltd., as a head of Medical Affairs Office
January 2005 Joined GlaxoSmithKline K.K.
September 2011 Professor of Departmen Faculty of Medicine, University of Yamanashi
September 2014 Professor of Department of Advanced Biomedical Research in Faculty of Medicine, University of Yamanashi (to present)
April 2015 Vice President of University of Yamanashi (to present)
December 2016 External Corporate Director of CMIC HOLDINGS Co., Ltd. (to present)
Status of Important Concurrent Posts
-Program Officer, Japan Agency for Medical Research and Development
-Visiting Professor, Juntendo University School of Medicine
-Visiting Professor, Ehime University School of Medicine
 

Takeshi Karasawa
External Corporate Director

April 1980 Joined Ministry of Health and Welfare (currently Ministry of Health, Labour and Welfare) July 2000 Director, Public Relations Office, General Coordination Division, Minister’s Secretariat, Ministry of Health and Welfare
July 2004 Director, National Health Insurance Division and Director, General Affairs Division, Health Insurance Bureau, Ministry of Health, Labour and Welfare
July 2009 Deputy Director-General (in charge of Medical Insurance, Health Policy, Health Care and Long-term Care Integration), Ministry of Health, Labour and Welfare
Sept. 2012 Director-General for Policy Planning and Evaluation (in charge of Social Security), Ministry of Health, Labour and Welfare
July 2014 Director General, Health Insurance Bureau, Ministry of Health, Labour and Welfare
June 2016 Director-General for Regional Revitalization, Headquarters for Overcoming Population Decline and Vitalizing Local Economy in Japan, Cabinet Secretariat
August 2016 Retired from Cabinet Secretariat 
Status of Important Concurrent Posts
-Visiting Professor, Saku University
December 2018 External Corporate Director of CMIC HOLDINGS Co., Ltd. (to present)

Audit and Suvervisory Board Member

Hiroshi Nakamura
Audit and Supervisory Board Member

March 2000 Resigned from TONETS CORPORATION
April 2000 Joined CMIC HOLDINGS Co., Ltd.
March 2001 Board Director
October 2002 Managing Director and CFO of CMIC HOLDINGS Co., Ltd. Division head of Administration Division and Director of Finance and Accounting Department
October 2003 Vice President, Director, and CFO of CMIC HOLDINGS Co., Ltd.
October 2004 Vice President, Representative Director and CFO of CMIC HOLDINGS Co., Ltd.
December 2007 Resigned from Board Director of CMIC HOLDINGS Co., Ltd.
December 2009 Board Director of CMIC HOLDINGS Co., Ltd.
December 2010 Resigned from Board Director of CMIC HOLDINGS Co., Ltd.
December 2015 Audit and Supervisory Board Member of CMIC HOLDINGS Co., Ltd. (to present)

Yasuo Yoshimune
Audit and Supervisory Board Member

April 1972 Joined Mitsui Pharmaceuticals, Inc.
January 2001 Joined Nihon Schering K.K. (currently Bayer Yakuhin, Ltd.)
August 2005 Joined the Company, General Manager in charge of the Business Promotions Department (Tokyo)
July 2011 General Manager, Quality Management Promotion Office, Clinical Development Div. I, the Company
October 2012 General Manager, Resource Management Office, CMIC Co., Ltd.
October 2015 Business Planning Division, Site Support Institute Co., Ltd.
August 2018 Business Development Division, Site Support Institute Co., Ltd.(to present)
December 2018 Audit and Supervisory Board Member of CMIC HOLDINGS Co., Ltd. (to present)

Kei Hata
External Audit and Supervisory Board Member

April 1984 Admitted to the TOKYO BAR Association -Joined Kazama & Co. Law Offices (currently Hata & Co. Law Offices)
December 2015 External Audit and Supervisory Board Member of CMIC HOLDINGS Co., Ltd. (to present)

Eriko Kawai
External Audit and Supervisory Board Member

October 1981 Joined Nomura Research Institute, Ltd.
September 1985 Management Consultant, McKinsey & Company
October 1986 Fund Manager, Mercury Asset Management plc, SG Warburg
November 1995 Chief Investment Officer (CIO), Yamaichi Regent ABC Polska
July 1998 Joined Bank for International Settlements
October 2004 Senior Pension Fund Administrator, Organisation for Economic Co-operation and Development (OECD)
March 2008 Representative, Kawai Global Intelligence
April 2012 Professor, Institute for the Promotion of Excellence in Higher Education, Kyoto University
April 2013 Professor, Institute for Liberal Arts and Sciences, Kyoto University
April 2014 Professor, Graduate School of Advanced Integrated Studies in Human Survivability, Kyoto University (to present)
December 2017 Audit & Supervisory Board Member of CMIC HOLDINGS Co., Ltd. (to present)

Status of Important Concurrent Posts
-Professor, Graduate School of Advanced Integrated Studies in Human Survivability, Kyoto University
-Director, The Outlook Foundation
-Director, The Grew Bancroft Foundation
-Outside Director, Nikko Asset Management Co., Ltd.
December 2017 External Audit and Supervisory Board Member of CMIC HOLDINGS Co., Ltd. (to present)

Hidetoshi Watanabe
External Audit and Supervisory Board Member

November 1977 Joined Showa Audit Corporation (currently Ernst & Young ShinNihon LLC)
August 1981 Registered as Certified Public Accountant
August 2008 Executive Director, Ernst & Young ShinNihon LLC
August 2012 Senior Managing Director, Ernst & Young ShinNihon LLC
July 2014 Executive Vice President, Ernst & Young ShinNihon LLC
July 2016 Established Hidetoshi Watanabe Certified Public Accountant Office (to present)
June 2017 Outside Director, Audit and Supervisory Committee Member, Business Brain Showa-Ota Inc.(to present)
Status of Important Concurrent Posts
-Outside Director, Audit and Supervisory Committee Member, Business Brain Showa-Ota Inc.
December 2018 External Audit and Supervisory Board Member of CMIC HOLDINGS Co., Ltd. (to present)

SHARE